"Slovakia Pharmaceuticals & Healthcare Report Q3 2014" Published

The Slovakian government is planning to allocate EUR278mn (USD386.7mn) in EU funding to develop healthcare and medical infrastructure in Slovakia over the 2014-2020 period, reports news agency TASR. The government added that after adding contributions from the state budget, the total funds that have been allocated for developing healthcare infrastructure will be EUR300mn (USD417.3mn). The government plans to allocate these funds to projects in large university hospitals and developing integrated outpatient healthcare facilities in the country. Slovakia continues to be an attractive pharmaceutical market for large multi-nationals because it generally offers significant potential as a location for pharmaceutical research.

Full Report Details at
- http://www.fastmr.com/prod/852090_slovakia_pharmaceuticals_healthcare_report_q3.aspx?afid=301

Headline Expenditure Projections

* Pharmaceuticals: EUR1.67bn (USD2.20bn) in 2013 to EUR1.68bn (USD2.13bn) in 2014; 0.6% in local currency terms and -3.2% in US dollar terms. Figures in line with Q214.
* Healthcare: EUR6.00bn (USD7.92bn) in 2013 to EUR6.07bn (USD7.71bn) in 2014; 1.2% in local currency terms and -2.6% in US dollar terms. Slight revision downward owing to macroeconomic backdrop.

Risk/Reward Ratings

Slovakia's Risk rating indicates the country has one of the best business environments in the Central and Eastern European region, although its ranking is moderated by its less-than-stellar rewards score. Consequently, Slovakia has a RRR score of 55.2 out of 100, making it now the sixth most attractive pharmaceutical market in Central and Eastern Europe. This means the country has dropped by one position from Q214.

Key Trends And Developments

* In May 2014, Slovakia's health minister Zuzana Zvolenska stated that state-run hospitals should pay off their mounting debts at their own expense. Zvolenska added that any help from the state may only be supplementary. The government will address a report on the indebtedness of healthcare facilities in 2013 during a press conference.
* In 2013, around 13 teaching and university...

The Slovakia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Slovakia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovak pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Slovakia to test other views - a key input for successful budgeting and strategic business planning in the Slovak pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Egypt Pharmaceuticals & Healthcare Report Q3 2014
- Malaysia Pharmaceuticals & Healthcare Report Q3 2014
- Moldova Pharmaceuticals & Healthcare Report Q3 2014
- Peru Pharmaceuticals & Healthcare Report Q3 2014
- France Pharmaceuticals & Healthcare Report Q3 2014